Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLICD10C83.5C83.7C84.6C91.0-MeSHPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceGMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyChemotherapyChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabChemo-substanceRituximabNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenParacetamolPrednisoloneNo. Substances4Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorHoelzer DDiseaseHochmaligne B-ALL und B-NHL bei Erwachsenen, ErstlinieOriginGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaProtocols in Revision 1 protocol foundProtocols under revision.GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784 V1.0)
